1
|
Sun SQ, Tai JW, He W, Yu YJ, Feng ZQ, Sun Q, Tong KN, Shi K, Liu BC, Zhu M, Wei G, Fan J, Xie YM, Liao LS, Fung MK. Enhancing Light Outcoupling Efficiency via Anisotropic Low Refractive Index Electron Transporting Materials for Efficient Perovskite Light-Emitting Diodes. Adv Mater 2024:e2400421. [PMID: 38430204 DOI: 10.1002/adma.202400421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Revised: 02/25/2024] [Indexed: 03/03/2024]
Abstract
Thanks to the extensive efforts toward optimizing perovskite crystallization properties, high-quality perovskite films with near-unity photoluminescence quantum yield are successfully achieved. However, the light outcoupling efficiency of perovskite light-emitting diodes (PeLEDs) is impeded by insufficient light extraction, which poses a challenge to the further advancement of PeLEDs. Here, an anisotropic multifunctional electron transporting material, 9,10-bis(4-(2-phenyl-1H-benzo[d]imidazole-1-yl)phenyl) anthracene (BPBiPA), with a low extraordinary refractive index (ne ) and high electron mobility is developed for fabricating high-efficiency PeLEDs. The anisotropic molecular orientations of BPBiPA can result in a low ne of 1.59 along the z-axis direction. Optical simulations show that the low ne of BPBiPA can effectively mitigate the surface plasmon polariton loss and enhance the photon extraction efficiency in waveguide mode, thereby improving the light outcoupling efficiency of PeLEDs. In addition, the high electron mobility of BPBiPA can facilitate balanced carrier injection in PeLEDs. As a result, high-efficiency green PeLEDs with a record external quantum efficiency of 32.1% and a current efficiency of 111.7 cd A-1 are obtained, which provides new inspirations for the design of electron transporting materials for high-performance PeLEDs.
Collapse
Affiliation(s)
- Shuang-Qiao Sun
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Jing-Wen Tai
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Wei He
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - You-Jun Yu
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Zi-Qi Feng
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Qi Sun
- Macau Institute of Materials Science and Engineering (MIMSE), MUST-SUDA Joint Research Center for Advanced Functional Materials, Zhuhai MUST Science and Technology Research Institute, Macau University of Science and Technology, Taipa, Macau, 999078, P. R. China
| | - Kai-Ning Tong
- Institute of Materials Science, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong, 518055, P. R. China
| | - Kefei Shi
- Institute of Materials Science, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong, 518055, P. R. China
| | - Bo-Chen Liu
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Min Zhu
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Guodan Wei
- Institute of Materials Science, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong, 518055, P. R. China
| | - Jian Fan
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
| | - Yue-Min Xie
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
- Jiangsu Key Laboratory of Advanced Negative Carbon Technologies, Soochow University, Suzhou, Jiangsu, 215123, P.R. China
| | - Liang-Sheng Liao
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
- Macau Institute of Materials Science and Engineering (MIMSE), MUST-SUDA Joint Research Center for Advanced Functional Materials, Zhuhai MUST Science and Technology Research Institute, Macau University of Science and Technology, Taipa, Macau, 999078, P. R. China
| | - Man-Keung Fung
- Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, Jiangsu, 215123, P. R. China
- Macau Institute of Materials Science and Engineering (MIMSE), MUST-SUDA Joint Research Center for Advanced Functional Materials, Zhuhai MUST Science and Technology Research Institute, Macau University of Science and Technology, Taipa, Macau, 999078, P. R. China
| |
Collapse
|
2
|
Roger Chen YH, Lee WC, Liu BC, Yang PC, Ho CC, Hwang JS, Huang TH, Lin HH, Lo WC. Quantifying the potential effects of air pollution reduction on population health and health expenditure in Taiwan. Environ Pollut 2023; 336:122405. [PMID: 37597736 DOI: 10.1016/j.envpol.2023.122405] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Revised: 08/12/2023] [Accepted: 08/16/2023] [Indexed: 08/21/2023]
Abstract
Air pollution, particularly ambient fine particulate matter (PM2.5) pollution, poses a significant risk to public health, underscoring the importance of comprehending the long-term impact on health burden and expenditure at national and subnational levels. Therefore, this study aims to quantify the disease burden and healthcare expenditure associated with PM2.5 exposure in Taiwan and assess the potential benefits of reducing pollution levels. Using a comparative risk assessment framework that integrates an auto-aggressive integrated moving average model, we evaluated the avoidable burden of cardiopulmonary diseases (including ischemic heart disease, stroke, chronic obstructive pulmonary disease, lung cancer, and diabetes mellitus) and related healthcare expenditure under different air quality target scenarios, including status quo and target scenarios of 15, 10, and 5 μg/m3 reduction in PM2.5 concentration. Our findings indicate that reducing PM2.5 exposure has the potential to significantly alleviate the burden of multiple diseases. Comparing the estimated attributable disease burden and healthcare expenditure between reference and target scenarios from 2022 to 2050, the avoidable disability-adjusted life years were 0.61, 1.83, and 3.19 million for the 15, 10, and 5 μg/m3 target scenarios, respectively. Correspondingly, avoidable healthcare expenditure ranged from US$ 0.63 to 3.67 billion. We also highlighted the unequal allocation of resources and the need for policy interventions to address health disparities due to air pollution. Notably, in the 5 μg/m3 target scenario, Kaohsiung City stands to benefit the most, with 527,368 disability-adjusted life years avoided and US$ 0.53 billion saved from 2022 to 2050. Our findings suggest that adopting stricter emission targets can effectively reduce the health burden and associated healthcare expenditure in Taiwan. Overall, this study provides policymakers in Taiwan with valuable insights for mitigating the negative effects of air pollution by establishing a comprehensive framework for evaluating the co-benefits of air pollution reduction on healthcare expenditure and disease burden.
Collapse
Affiliation(s)
- Yi-Hsuan Roger Chen
- Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, MD, USA; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Wan-Chen Lee
- Institute of Environmental and Occupational Health Sciences, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Bo-Chen Liu
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Po-Chieh Yang
- Department of Industrial Economics, Tamkang University, Taipei, Taiwan
| | - Chi-Chang Ho
- Institute of Statistical Science, Academia Sinica, Taipei, Taiwan
| | | | - Tzu-Hsuan Huang
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; AbbVie Inc. North Chicago, Illinois, USA
| | - Hsien-Ho Lin
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Wei-Cheng Lo
- Master Program in Applied Epidemiology, College of Public Health, Taipei Medical University, Taipei, Taiwan; Taipei Medical University Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan.
| |
Collapse
|
3
|
Wang KJ, Xia QD, Ding F, Hu X, Liu BC. [Pulmonary nuclear protein of the testis midline carcinoma:a case report]. Zhonghua Jie He He Hu Xi Za Zhi 2023; 46:1019-1021. [PMID: 37752046 DOI: 10.3760/cma.j.cn112147-20230316-00134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/28/2023]
Abstract
Nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare malignant epithelial tumor that typically occurs in the midline regions such as the head, neck, and mediastinum. This tumor is characterized by rapid development, aggressive growth, and strong invasiveness. Due to its short duration, most patients are diagnosed at advanced stages, often leading to rapid mortality. Although reports on pulmonary NUT carcinoma are uncommon, this article presents a case of pulmonary NUT carcinoma in which the patient repeatedly expectorated bronchial casts and tumor tissue. Additionally, a comprehensive review of relevant literature from recent years is provided to enhance understanding of this disease.
Collapse
Affiliation(s)
- K J Wang
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - Q D Xia
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - F Ding
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - X Hu
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| | - B C Liu
- Bishan Hospital Afflicted of Chongqing Medical University, Chongqing 402260, China
| |
Collapse
|
4
|
Yang M, Hou SM, Yuan L, Wang M, Zheng J, Lu KQ, Yan Y, Zhang SY, Li M, Cao JY, Yang M, Zhang XL, Liu H, Liu BC, Wang Y, Wang B. [The consistency of skeletal muscle mass measured by CT at L 1 and L 3 levels and the correlation of skeletal muscle density at L 1 level with prognosis in dialysis patients]. Zhonghua Yi Xue Za Zhi 2023; 103:2850-2858. [PMID: 37726991 DOI: 10.3760/cma.j.cn112137-20230608-00970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
Objective: To investigate the consistency of skeletal muscle mass by CT at 1st lumbar vertebrae (L1) and 3rd lumbar vertebrae (L3) levels and the correlation of skeletal muscle density (SMD) at L1 level with prognosis in dialysis patients. Methods: A total of 1 020 patients who underwent initial dialysis and had CT examination data in four centers (Zhongda Hospital Affiliated to Southeast University, the Third Affiliated Hospital of Soochow University, Taizhou People's Hospital Affiliated to Nanjing Medical University and the Affiliated Hospital of Yangzhou University) from January 2014 to December 2019 were retrospectively collected. The skeletal muscle index (SMI) and SMD at L1 and L3 CT images were measured and calculated in patients with both L1 and L3 level CT images. The consistency of SMI and SMD at L1 and L3 levels was analyzed, and the cut-off value of SMI and SMD at L1 level for predicting all-cause mortality and their correlation with the prognosis of dialysis patients were studied. Cox regression model was used to analyze the risk factors for all-cause death and cardiac death. Results: A total of 383 patients had both L1 and L3 level images, including 233 males and 150 females. The average SMD value of 16 samples (4.2%) exceeded the 95% consistency limit range (-8.71 to 7.75 HU), and the average SMI value of 15 samples (3.9%) exceeded the 95% consistency limit range (-20.45 to 9.53 HU). The optimal cut-off value of SMD at L1 level for predicting all-cause mortality was 36.46 HU and the area under curve (AUC) of receiver operating characteristic (ROC) curve was 0.658 (95%CI: 0.596-0.721, P<0.001), with the sensitivity and specificity of 83.8% and 57.5%, respectively. SMI at L1 level was not significantly associated with all-cause mortality (P=0.299). Multivariate Cox regression analysis showed that low SMD at L1 level was associated with all-cause mortality (HR=2.861, 95%CI: 1.576-5.193, P=0.001) and cardiac death (HR=3.771, 95%CI:1.462-9.724, P=0.006). Conclusions: SMD at L1 levelis consistent with SMD at L3 level and can be used to evaluate muscle mass. Low SMD is a risk factor for mortality in dialysis patients.
Collapse
Affiliation(s)
- M Yang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - S M Hou
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - L Yuan
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - M Wang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - J Zheng
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - K Q Lu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - Y Yan
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - S Y Zhang
- Department of Nephrology, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou 225300, China
| | - M Li
- Department of Nephrology, the Third Affiliated Hospital of Soochow University, Changzhou 213000, China
| | - J Y Cao
- Department of Nephrology, Taizhou People's Hospital Affiliated to Nanjing Medical University, Taizhou 225300, China
| | - M Yang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - X L Zhang
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - H Liu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - B C Liu
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - Y Wang
- Department of Nephrology, Affiliated Hospital of Yangzhou University, Yangzhou 225001, China
| | - B Wang
- Institute of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| |
Collapse
|
5
|
Zhang XS, Liu BC, Du X, Zhang YL, Xu N, Liu XL, Li WM, Lin H, Liang R, Chen CY, Huang J, Yang YF, Zhu HL, Pan L, Wang XD, Li GH, Liu ZG, Zhang YQ, Liu ZF, Hu JD, Liu CS, Li F, Yang W, Meng L, Han YQ, Lin LE, Zhao ZY, Tu CQ, Zheng CF, Bai YL, Zhou ZP, Chen SN, Qiu HY, Yang LJ, Sun XL, Sun H, Zhou L, Liu ZL, Wang DY, Guo JX, Pang LP, Zeng QS, Suo XH, Zhang WH, Zheng YJ, Jiang Q. [To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:728-736. [PMID: 38049316 PMCID: PMC10630575 DOI: 10.3760/cma.j.issn.0253-2727.2023.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Indexed: 12/06/2023]
Abstract
Objective: To analyze and compare therapy responses, outcomes, and incidence of severe hematologic adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia (CML) . Methods: Data of patients with chronic phase CML diagnosed between January 2006 and November 2022 from 76 centers, aged ≥18 years, and received initial flumatinib or imatinib therapy within 6 months after diagnosis in China were retrospectively interrogated. Propensity score matching (PSM) analysis was performed to reduce the bias of the initial TKI selection, and the therapy responses and outcomes of patients receiving initial flumatinib or imatinib therapy were compared. Results: A total of 4 833 adult patients with CML receiving initial imatinib (n=4 380) or flumatinib (n=453) therapy were included in the study. In the imatinib cohort, the median follow-up time was 54 [interquartile range (IQR), 31-85] months, and the 7-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.2%, 88.4%, 78.3%, and 63.0%, respectively. The 7-year FFS, PFS, and OS rates were 71.8%, 93.0%, and 96.9%, respectively. With the median follow-up of 18 (IQR, 13-25) months in the flumatinib cohort, the 2-year cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) were 95.4%, 86.5%, 58.4%, and 46.6%, respectively. The 2-year FFS, PFS, and OS rates were 80.1%, 95.0%, and 99.5%, respectively. The PSM analysis indicated that patients receiving initial flumatinib therapy had significantly higher cumulative incidences of CCyR, MMR, MR(4), and MR(4.5) and higher probabilities of FFS than those receiving the initial imatinib therapy (all P<0.001), whereas the PFS (P=0.230) and OS (P=0.268) were comparable between the two cohorts. The incidence of severe hematologic adverse events (grade≥Ⅲ) was comparable in the two cohorts. Conclusion: Patients receiving initial flumatinib therapy had higher cumulative incidences of therapy responses and higher probability of FFS than those receiving initial imatinib therapy, whereas the incidence of severe hematologic adverse events was comparable between the two cohorts.
Collapse
Affiliation(s)
- X S Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
| | - B C Liu
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - X Du
- The Second People's Hospital of Shenzhen, Shenzhen 518035, China
| | - Y L Zhang
- Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - N Xu
- Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - X L Liu
- Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - W M Li
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - H Lin
- First Hospital of Jilin University, Changchun 130021, China
| | - R Liang
- Xijing Hospital, Airforce Military Medical University, Xi'an 710032, China
| | - C Y Chen
- Qilu Hospital of Shandong University, Jinan 250012, China
| | - J Huang
- The Fourth Affiliated Hospital of Zhejiang University, Hangzhou 322000, China
| | - Y F Yang
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - H L Zhu
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - L Pan
- Institute of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - X D Wang
- Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu 610072, China
| | - G H Li
- Xi'an International Medical Center Hospital, Xi'an 710038, China
| | - Z G Liu
- Shengjing Hospital of China Medical University, Shenyang 110020, China
| | - Y Q Zhang
- The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
| | - Z F Liu
- The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
| | - J D Hu
- Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - C S Liu
- First Hospital of Jilin University, Changchun 130021, China
| | - F Li
- The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - W Yang
- Shengjing Hospital of China Medical University, Shenyang 110020, China
| | - L Meng
- Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
| | - Y Q Han
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
| | - L E Lin
- Hainan General Hospital, Haikou 570311, China
| | - Z Y Zhao
- Hainan General Hospital, Haikou 570311, China
| | - C Q Tu
- Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen 518101, China
| | - C F Zheng
- Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen 518101, China
| | - Y L Bai
- Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China
| | - Z P Zhou
- The Second Hospital Affiliated to Kunming Medical University, Kunming 650106, China
| | - S N Chen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou 215006, China
| | - H Y Qiu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou 215006, China
| | - L J Yang
- Xi'an International Medical Center Hospital, Xi'an 710117, China
| | - X L Sun
- The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
| | - H Sun
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
| | - L Zhou
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Z L Liu
- Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen 518000, China
| | - D Y Wang
- Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen 518000, China
| | - J X Guo
- The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
| | - L P Pang
- Peking University Shenzhen Hospital, Shenzhen 516473, China
| | - Q S Zeng
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
| | - X H Suo
- Handan Central Hospital, Handan 057150, China
| | - W H Zhang
- First Hospital of Shangxi Medical University, Taiyuan 300012, China
| | - Y J Zheng
- First Hospital of Shangxi Medical University, Taiyuan 300012, China
| | - Q Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
| |
Collapse
|
6
|
Ai LL, Lai AL, Qin XH, Liu BC, Li J, Wang JX, Zhu P. [Application and clinical significance of intercellular proximity labeling technique in chronic myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:543-549. [PMID: 37749032 PMCID: PMC10509616 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Indexed: 09/27/2023]
Abstract
Objective: This study aimed to explore the application of interaction-dependent fucosyl-biotinylation (FucoID), a chemical biology-based proximity labeling technique, in capturing tumor antigen-specific T cells and its clinical value in chronic myelogenous leukemia (CML) . Methods: Flow cytometry and fluorescence microscopy were employed to evaluate the experimental parameters for FucoID in CML. Peripheral blood samples were obtained from 14 newly diagnosed CML patients in the chronic phase. These samples underwent flow cytometry-based sorting and were subsequently labeled with FucoID to facilitate the isolation of tumor cells and T cells, followed by the immunophenotypic identification of tumor antigen-specific T cells. Finally, the diagnostic and therapeutic potential of FucoID in CML was assessed. Results: Initially, the experimental parameters for FucoID in CML were established. The proportion of CD3(+) T cells in patients was (8.96±6.47) %, exhibiting a marked decrease compared with that in healthy individuals at (38.89±22.62) %. The proportion of tumor-specific antigen-reactive T cells was (3.34±4.49) %, which demonstrated interpatient variability. In addition, the proportion of tumor-specific antigen-active T cells in CD4(+) T cells was (3.95±1.72) %, which was generally lower than the proportion in CD8(+) T cells at (5.68±2.18) %. Compared with those in tumor-specific antigen-nonreactive T cells, CCR7(-)CD45RA(-) effector memory T cells and CCR7(-)CD45RA(+) effector T cells were highly enriched in tumor-specific antigen-reactive T cells. Moreover, the intensity of tumor immune reactivity in patients exhibited a significant correlation with white blood cell count (WBC) and hemoglobin (HGB) levels in peripheral blood, while no such correlation was observed with other clinical baseline characteristics. Conclusion: The combination of FucoID and flow cytometry enables the rapid identification and isolation of tumor antigen-specific T cells in CML. The successful application of this method in CML and the implications of our findings suggest its potential clinical value in the field of hematologic malignancies.
Collapse
Affiliation(s)
- L L Ai
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - A L Lai
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - X H Qin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - J Li
- State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| | - P Zhu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China
| |
Collapse
|
7
|
Yeh TL, Chen YHR, Hsu HY, Tsai MC, Wu YC, Lo WC, Huang TH, Liu BC, Lin HH, Chien KL. Cardiovascular Disease Burden Attributable to High Body Mass Index in Taiwan. Acta Cardiol Sin 2023; 39:628-642. [PMID: 37456949 PMCID: PMC10346049 DOI: 10.6515/acs.202307_39(4).20221219c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 12/19/2022] [Indexed: 07/18/2023]
Abstract
Background Studies on disease burden in Taiwan are lacking. We aimed to quantify the burden of cardiovascular disease (CVD) attributable to high body mass index (BMI) in Taiwan. Methods Using a comparative risk assessment approach from the Global Burden of Disease study, we estimated the population attributable fraction (PAF), attributable CVD burden, and disability-adjusted life years (DALYs) according to sex, age, and area of residence in Taiwan. The BMI distribution for the population was obtained from the National Health Interview Survey in 2013. CVD was defined as an ischemic heart disease or stroke. Results The attributable PAF for CVD from high BMI was 18.0% (19.6% in men and 15.6% in women), and it was highest (42.7%) in those aged 25-30 years. Adults aged 60-65 years had the highest absolute DALYs (11,546). The average relative age-standardized attributable burden was 314 DALYs per 100,000 person-years, and it was highest in those aged 75-80 years (1,407 DALYs per 100,000 person-years). Those living in Taitung County had the highest PAF of 21.9% and the highest age-standardized attributable burden (412 DALYs). Conclusions In Taiwan, an 18% reduction in CVDs could be achieved if obesity/overweight was prevented. Prevention was most effective in early adulthood. The absolute CVD burden from obesity/overweight was highest in middle-aged men, and the relative burden was highest in older adults. Resource allocation in targeted populations and specific areas to eliminate CVD and health inequities is urgently required.
Collapse
Affiliation(s)
- Tzu-Lin Yeh
- Department of Family Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu City
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Yi-Hsuan Roger Chen
- Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, United States
| | - Hsin-Yin Hsu
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- Department of Family Medicine, Taipei MacKay Memorial Hospital, Taipei
- Department of Medicine, MacKay Medical Collage
| | - Ming-Chieh Tsai
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- Department of Medicine, MacKay Medical Collage
- Division of Endocrinology, Department of Internal Medicine, MacKay Memorial Hospital, Tamsui Branch, New Taipei City
| | - Yun-Chun Wu
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Wei-Cheng Lo
- Master Program in Applied Epidemiology, College of Public Health, Taipei Medical University, Taipei, Taiwan
| | - Tzu-Hsuan Huang
- Population Neuroscience and Genetics Lab, Center for Human Development, UC San Diego, San Diego, United States
| | - Bo-Chen Liu
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - Hsien-Ho Lin
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- Master of Global Health Program, College of Public Health, National Taiwan University
| | - Kuo-Liong Chien
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| |
Collapse
|
8
|
Wang HY, Liu BC. [Exploration and expectation of magnetic resonance imaging in the evaluation of prostate cancer]. Zhonghua Yi Xue Za Zhi 2023; 103:1435-1438. [PMID: 37198104 DOI: 10.3760/cma.j.cn112137-20230302-00317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
With the progress of imaging technology, magnetic resonance imaging (MRI) has become the preferred imaging method for prostate cancer due to its excellent soft tissue resolution and the capability of multiparametric and multi-planar imaging. This paper briefly describes the current application and research progress of MRI in the preoperative qualitative diagnosis, staging assessment and postoperative recurrence monitoring of prostate cancer. The purpose is to deepen the understanding of clinicians and radiologists on the value of MRI in prostate cancer, and to promote the exploration of MRI in the management of prostate cancer.
Collapse
Affiliation(s)
- H Y Wang
- Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| | - B C Liu
- Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
9
|
Liu BC, Wang HY, Dong Z, Zhang Y, Bai X, Ding XH, Zhang XJ, Xu W, Zhao J, Hao YW, Ye HY. [Diagnostic value of multiparametric MRI-based models in the assessment of extra-prostatic extension of prostate cancer]. Zhonghua Yi Xue Za Zhi 2023; 103:1439-1445. [PMID: 37198105 DOI: 10.3760/cma.j.cn112137-20221215-02656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Objective: To evaluate the diagnostic value of multiparametric magnetic resonance imaging (mpMRI) based models in the assessment of extra-prostatic extension (EPE) of prostate cancer. Methods: This retrospective study included 168 consecutive men with prostate cancers [aged 48 to 82 (66.6±6.8) years] who underwent radical prostatectomy and preoperative mpMRI examinations at the First Medical Center of the PLA General Hospital from January 2021 to February 2022. According to European Society of Urogenital Radiology (ESUR) score, EPE grade and mEPE score, all cases were independently evaluated by two radiologists, with disagreement reviewed by a senior radiologist as the final result. The diagnostic performance of each MRI-based model for pathologic EPE prediction was assessed using receiver operating characteristic curve (ROC), and the differences between the corresponding area under the curve (AUC) were compared using the DeLong test. The weighted Kappa test was used to evaluate the inter-reader agreement of each MRI-based model. Results: A total of 62 (36.9%) prostate cancer patients had pathologic confirmed EPE after radical prostatectomy. The AUC of ESUR score, EPE grade and mEPE score for predicting pathologic EPE were 0.836 (95%CI: 0.771-0.888), 0.834 (95%CI: 0.769-0.887) and 0.785 (95%CI: 0.715-0.844), respectively. The AUC of ESUR score and EPE grade were both superior to that of mEPE score with significant differences (all P<0.05), while there was no significant difference between the ESUR score and EPE grade models (P=0.900). EPE grading and mEPE score had good inter-reader consistency, with weighted Kappa values of 0.65 (95%CI: 0.56-0.74) and 0.74 (95%CI: 0.64-0.84), respectively. The inter-reader consistency of ESUR score was moderate, and the weighted Kappa value was 0.52 (95%CI: 0.40-0.63). Conclusion: All MRI-based models showed good preoperative diagnostic value in predicting EPE, among which the EPE grade resulted in more reliable performance with substantial inter-reader agreement.
Collapse
Affiliation(s)
- B C Liu
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - H Y Wang
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Z Dong
- Department of Radiology, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
| | - Y Zhang
- Department of Radiology, the Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
| | - X Bai
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - X H Ding
- Department of Pathology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - X J Zhang
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - W Xu
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - J Zhao
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - Y W Hao
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| | - H Y Ye
- Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
| |
Collapse
|
10
|
Tai KY, Liu BC, Hsiao CH, Tsai MC, Lin FYS. A Near-Optimal Energy Management Mechanism Considering QoS and Fairness Requirements in Tree Structure Wireless Sensor Networks. Sensors (Basel) 2023; 23:763. [PMID: 36679560 PMCID: PMC9865159 DOI: 10.3390/s23020763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 12/30/2022] [Accepted: 01/06/2023] [Indexed: 06/17/2023]
Abstract
The rapid development of AIOT-related technologies has revolutionized various industries. The advantage of such real-time sensing, low costs, small sizes, and easy deployment makes extensive use of wireless sensor networks in various fields. However, due to the wireless transmission of data, and limited built-in power supply, controlling energy consumption and making the application of the sensor network more efficient is still an urgent problem to be solved in practice. In this study, we construct this problem as a tree structure wireless sensor network mathematical model, which mainly considers the QoS and fairness requirements. This study determines the probability of sensor activity, transmission distance, and transmission of the packet size, and thereby minimizes energy consumption. The Lagrangian Relaxation method is used to find the optimal solution with the lowest energy consumption while maintaining the network's transmission efficiency. The experimental results confirm that the decision-making speed and energy consumption can be effectively improved.
Collapse
Affiliation(s)
- Kuang-Yen Tai
- Department of Information Management, National Taiwan University, Taibei 106, Taiwan
| | - Bo-Chen Liu
- Department of Information Management, National Taiwan University, Taibei 106, Taiwan
| | - Chiu-Han Hsiao
- Research Center for Information Technology Innovation, Academia Sinica, Taibei 115, Taiwan
| | - Ming-Chi Tsai
- Department of Information Management, National Taiwan University, Taibei 106, Taiwan
| | - Frank Yeong-Sung Lin
- Department of Information Management, National Taiwan University, Taibei 106, Taiwan
| |
Collapse
|
11
|
Cui MQ, He B, Xu W, Hao YW, Ding XH, Wang S, Bai X, Liu BC, Ye HY, Wang HY. [Value of clear cell likelihood score in differentiation between renal oncocytoma and clear cell renal cell carcinoma]. Zhonghua Yi Xue Za Zhi 2022; 102:3779-3785. [PMID: 36517429 DOI: 10.3760/cma.j.cn112137-20221020-02193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Objective: To evaluate the value of clear cell likelihood score (ccLS) in identifying renal oncocytoma (RO) and clear cell renal cell carcinoma (ccRCC). Methods: Retrospective data of pathologically confirmed 43 RO patients [24 men and 19 women, aged 22-77 (54±14) years] between February 2008 and September 2021 and 43 ccRCC patients [30 men and 13 women, aged 29-78 (56±12) years] between May and July 2021 were consecutively included in the department of radiology, Chinese PLA General Hospital. Two radiologists used ccLS to assess each case independently, and disagreements were resolved by consensus. The ability of ccLS to identify RO and ccRCC was examined by the receiver operating characteristic (ROC) curve which identified the best optimal diagnostic cut-off values, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value. Results: The mean tumor diameter was 3.8 cm in RO patients and 3.7 cm in ccRCC patients. Central scar and segmental enhancement inversion (SEI) were more frequently observed in the RO group compared to the ccRCC group [53.5% (23∶43) versus 11.6% (5∶43) and 41.9% (18∶43) versus 7.0% (3∶43), respectively], with statistical differences (P<0.001). The ccLS scores in the RO group ranged from 1 to 4, while 79.0% of the cases were 3. The ccLS scores in the ccRCC group ranged from 2 to 5, while 72% of the cases were 4. The scores of the two groups were statistically different (P<0.001). The ccLS showed the best performance when the threshold was 4 according to the ROC curve. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of ccLS for distinguishing RO from ccRCC were 83.7%, 90.7%, 87.2%, 90.0%, and 84.8%, respectively, and the area under the ROC curve value was 0.879. Conclusion: The ccLS has credible sensitivity and specificity in differentiating renal oncocytoma from clear cell carcinoma, which may be helpful for the preoperative diagnosis.
Collapse
Affiliation(s)
- M Q Cui
- Medical School of Chinese PLA, Beijing 100853, China
| | - B He
- Department of Radiology, Zibo Centre Hospital, Zibo 255036, China
| | - W Xu
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - Y W Hao
- Medical School of Chinese PLA, Beijing 100853, China
| | - X H Ding
- Department of Pathology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - S Wang
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - X Bai
- Department of Radiology, the Fifth Medical Centre, PLA General Hospital, Beijing 100039, China
| | - B C Liu
- Medical School of Chinese PLA, Beijing 100853, China
| | - H Y Ye
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| | - H Y Wang
- Department of Radiology, the First Medical Centre, PLA General Hospital, Beijing 100853, China
| |
Collapse
|
12
|
An XY, Hu LX, Li M, Liu BC, Wang RQ, Nan YM. [A study on treatment timing selection and short-term efficacy prediction with changes in cytokine levels before and after non-biological artificial liver treatment in acute-on-chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2022; 30:1218-1224. [PMID: 36891701 DOI: 10.3760/cma.j.cn501113-20220524-00278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
Abstract
Objective: To investigate the efficacy and diagnostic accuracy of changes in cytokine levels before and after non-biological artificial liver (referred to as ABL) treatment in patients with acute-on-chronic liver failure (ACLF) in order to establish a basis for treatment timing selection and short-term (28d) prognosis. Methods: 90 cases diagnosed with ACLF were selected and divided into a group receiving artificial liver treatment (45 cases) and a group not receiving artificial liver treatment (45 cases). Age, gender, first routine blood test after admission, liver and kidney function, and procalcitonin (PCT) of the two groups were collected. The 28-day survival of the two groups was followed-up for survival analysis. The 45 cases who received artificial liver therapy were further divided into an improvement group and a deterioration group according to the clinical manifestations before discharge and the last laboratory examination results as the efficacy evaluation indicators. Routine blood test, coagulation function, liver and kidney function, PCT, alpha fetoprotein (AFP), β-defensin-1 (HBD-1), 12 cytokines and other indicators were analyzed and compared. A receiver operating characteristic curve (ROC curve) was used to analyze the diagnostic efficacy of the short-term (28 d) prognosis and an independent risk factors affecting the prognosis of ACLF patients. According to different data, Kaplan-Meier method, log-rant test, t-test, Mann-Whitney U test, Wilcoxon rank-sum test, χ2 test, Spearman rank correlation analysis and logistic regression analysis were used for statistical analysis. Results: The 28-day survival rate was significantly higher in ACLF patients who received artificial liver therapy than that of those who did not receive artificial liver therapy (82.2% vs. 61.0%, P<0.05). The levels of serum HBD-1, alpha interferon (IFN-α) and interleukin-5 (IL-5) after artificial liver treatment were significantly lower in ACLF patients than those before treatment (P<0.05), while liver and coagulation function were significantly improved compared with those before treatment (P<0.05), and there was no statistically significant difference in other serological indexes before and after treatment (P>0.05). Before artificial liver treatment, serum HBD-1 and INF-α levels were significantly lower in the ACLF improvement group than in the deterioration group (P<0.05) and were positively correlated with the patients' prognosis (deteriorating) (r=0.591, 0.427, P<0.001, 0.008). The level of AFP was significantly higher in the improved ACLF group than that in the deterioration group (P<0.05), and was negatively correlated with the prognosis (deteriorating) of the patients (r=-0.557, P<0.001). Univariate logistic regression analysis showed that HBD-1, IFN-α and AFP were independent risk factors for the prognosis of ACLF patients (P=0.001, 0.043, and 0.036, respectively), and that higher HBD-1 and IFN-α levels were associated with lower AFP level and a deteriorating prognosis. The area under the curve (AUC) of HBD-1, IFN-α, and AFP for short-term (28d) prognostic and diagnostic efficacy of ACLF patients was 0.883, 0.763, and 0.843, respectively, and the sensitivity and specificty was 0.75, 0.75, and 0.72, and 0.84, 0.80, and 0.83, respectively. The combination of HBD-1 and AFP had further improved the diagnostic efficiency of short-term prognosis of ACLF patients (AUC=0.960, sensitivity and specificity: 0.909 and 0.880 respectively). The combination of HBD-1+IFN-α+AFP had the highest diagnostic performance, with an AUC of 0.989, sensitivity of 0.900, and specificity of 0.947. Conclusion: Artificial liver therapy can effectively improve the clinical symptoms and liver and coagulation function of patients with ACLF; remove cytokines such as HBD-1, IFN-α, and IL-5 in patients with liver failure; delay or reverse the progression of the disease; and improve the survival rate of patients. HBD-1, IFN-α, and AFP are independent risk factors affecting the prognosis of ACLF patients, which can be used as biological indicators for evaluating the short-term prognosis of ACLF patients. The higher the level of HBD-1 and/or IFN-α, the higher the risk of disease deterioration. Therefore, artificial liver therapy should be started as soon as possible after the exclusion of infection. In diagnosing the prognosis of ACLF, HBD-1 has higher sensitivity and specificity than IFN-α and AFP, and its diagnostic efficiency is greatest when combined with IFN-α and AFP.
Collapse
Affiliation(s)
- X Y An
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - L X Hu
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - M Li
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - B C Liu
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - R Q Wang
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| | - Y M Nan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
| |
Collapse
|
13
|
Cook NE, Kissinger-Knox A, Iverson IA, Liu BC, Iverson GL. A-11 Social Determinants of Health in the Diagnosis and Management of Pediatric Concussion: A Content Analysis. Arch Clin Neuropsychol 2022. [DOI: 10.1093/arclin/acac32.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purpose: This content analysis examined the literature underlying the Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children (i.e., the “Guideline”) to determine the extent to which social determinants of health (SDH) were examined or addressed. Methods: A published systematic review, that formed the basis for the Guideline, included 37 studies addressing diagnosis, prognosis, and treatment/rehabilitation. We examined those studies to identify SDH domains and associated subcategories derived from the Healthy People 2020 and 2030 websites. Pairs of raters coded each article with disagreements resolved by consensus. Results: At least one SDH domain was represented in 60% of the articles, usually mentioned descriptively, as a covariate, or as a design consideration. Very few were addressed as a primary focus of the study. The most frequently represented SDH domain was Education Access (43.2% of studies), receiving credit most often for reporting on participants with learning disabilities. Social and Community Context, broadly defined, was represented in nearly 1 of 3 studies (29.7%). Economic Stability and Health Care Access domains were included in 6 studies (16.2%). Some studies (k = 6, 16.2%) referenced SDH as important to consider for future research. The Guideline includes some commentary on health literacy and socioeconomic status. Conclusions: Social determinants of health are largely unrepresented as important or meaningful variables influencing the Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children, or in the studies included in the systematic review that informed the guideline.
Collapse
|
14
|
Liu BC, Gaudet CE, Schatz P, Berkner P, Iverson GL. A-26 The Prevalence of Invalid Baseline ImPACT® Test Scores in Adolescent Student Athletes. Arch Clin Neuropsychol 2022. [DOI: 10.1093/arclin/acac32.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Purpose: Immediate Post-Concussion and Cognitive Testing (ImPACT®) is among the most commonly used neuropsychological measures to establish a baseline estimate of neuropsychological functioning for concussion management. We sought to identify correlates of invalid performance on ImPACT® baseline testing in adolescents. Methods: The sample included 67,009 English-speaking adolescents (ages 14–18, mean: 15.51, SD: 1.22) who completed ImPACT® baseline tests in English between 2009 and 2019. The association between invalid performance (as determined by the embedded invalidity indicators) and demographic and health variables was assessed using chi-square tests and with odds ratios (OR). Results: Overall, 7.2% of adolescents produced invalid baseline tests. Boys (7.9%) produced more invalid baselines than girls (6.2%; χ2 = 70.35, p < 0.001, OR = 1.29, 95% CI = 1.22, 1.37). Adolescents with learning disabilities (16.4%), attention-deficit/hyperactivity disorder (11.1%), and those who have received special education services (16.0%) or repeated more than 1 year of school (11.0%), all obtained invalid baselines at higher frequencies than those who did not endorse these variables (i.e., 6.5%–6.8%; p < 0.001). Adolescents who reported receiving treatment for headaches (9.5%), migraines (9.4%), epilepsy/seizures (11.1%), substance/alcohol use (17.0%), or a psychiatric condition (10.0%) obtained invalid baselines at higher frequencies than those who did not (i.e., 6.6%–6.9%; p < 0.001). Conclusions: Consistent with prior research, approximately 7% of adolescents produced invalid baselines. However, the frequencies of invalid performances were substantially greater for subgroups such as those with learning disabilities, those who have received special education services, and youth who have received past substance abuse treatment.
Collapse
|
15
|
Yang MZ, Li L, Wei H, Liu BC, Liu KQ, Li DP, Zhang L, Yang RC, Mi YC, Wang JX, Wang Y. [Clinical and genetic characteristics of patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective of 790 cases]. Zhonghua Xue Ye Xue Za Zhi 2022; 43:336-341. [PMID: 35680634 PMCID: PMC9189486 DOI: 10.3760/cma.j.issn.0253-2727.2022.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Indexed: 11/05/2022]
Abstract
Objective: To retrospectively analyze the data of Chinese patients with newly diagnosed acute promyelocytic leukemia (APL) to preliminarily discuss the clinical and cytogenetic characteristics. Methods: From February 2004 to June 2020, patients with newly diagnosed APL aged ≥ 15 years who were admitted to the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College were chosen. Clinical and laboratory features were retrospectively analyzed. Results: A total of 790 cases were included, with a male to female ratio of 1.22. The median age of the patients was 41 (15-76) years. Patients aged between 20 and 59 predominated, with 632 patients (80%) of 790 patients classified as low and intermediate risk and 158 patients (20%) of 790 patients classified as high risk. The white blood cell, platelet, and hemoglobin levels at diagnosis were 2.3 (0.1-176.1) ×10(9)/L, 29.5 (2.0-1220.8) ×10(9)/L, and 89 (15-169) g/L, respectively, and 4.8% of patients were complicated with psoriasis. The long-form type of PML-RARα was most commonly seen in APL, accounting for 58%. Both APTT extension (10.3%) and creatinine>14 mg/L (1%) are rarely seen in patients at diagnosis. Cytogenetics was performed in 715 patients with newly diagnosed APL. t (15;17) with additional chromosomal abnormalities were found in 155 patients, accounting for 21.7%; among which, +8 was most frequently seen. A complex karyotype was found in 64 (9.0%) patients. Next-generation sequencing was performed in 178 patients, and 113 mutated genes were discovered; 75 genes had an incidence rate>1%. FLT3 was the most frequently seen, which accounted for 44.9%, and 20.8% of the 178 patients present with FLT3-ITD. Conclusions: Patients aged 20-59 years are the most common group with newly diagnosed APL. No obvious difference was found in the ratio of males to females. In terms of risk stratification, patients divided into low and intermediate risk predominate. t (15;17) with additional chromosomal abnormalities accounted for 21% of 715 patients, in which +8 was most commonly seen. The long-form subtype was most frequently seen in PML-RARα-positive patients, and FLT3 was most commonly seen in the mutation spectrum of APL.
Collapse
Affiliation(s)
- M Z Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D P Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R C Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
16
|
Wang WN, Min Z, Wu JR, Liu BC, Xu XL, Fang YL, Ju YL. Physiological and transcriptomic analysis of Cabernet Sauvginon (Vitis vinifera L.) reveals the alleviating effect of exogenous strigolactones on the response of grapevine to drought stress. Plant Physiol Biochem 2021; 167:400-409. [PMID: 34411779 DOI: 10.1016/j.plaphy.2021.08.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 08/05/2021] [Accepted: 08/07/2021] [Indexed: 06/13/2023]
Abstract
Drought stress can significantly affect the growth and yield of grapevine. The application of exogenous strigolactone can relieve the drought symptoms of grapevine; however, little is known about the transcription levels in grapevine under drought stress following exogenous strigolactone application. The mitigative effect of exogenous strigolactone on grapevine leaves under drought stress was studied by transcriptome analysis based on RNA sequencing. On the 10th day of drought stress, the strigolactone treatment group had a higher relative water content and lower electrical conductivity, which significantly alleviated the drought damage. Compared to the drought (D) group, a total of 5955 differentially expressed genes (DEGs) (2966 up-regulated genes and 2989 down-regulated genes) were detected in the exogenous strigolactone (DG) groups. Based on Gene Ontology analysis, the DEGs in the D and DG treatments were enriched in the processes of photosynthesis and organic acid catabolism. Pathway analysis showed that the DEGs in the D and DG treatments were enriched in carbon metabolism, ribosome, starch and sucrose metabolism, flavonoid biosynthesis, and circadian rhythm. Additionally, in the DG group, the antioxidant enzyme genes of CAT1, GSHPX1, GSHPX2, POD42, APX6, and SODCP were up-regulated, two NAC, three WRKY, and four MYB transcription factor genes were down-regulated, and the key gene of strigolactone synthesis D14 was up-regulated, compared with that in the D group. The results provide a new perspective for studying the adaptation of plants to drought stress.
Collapse
Affiliation(s)
- Wan-Ni Wang
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China
| | - Zhuo Min
- Department of Brewing Engineering, Moutai University, Renhuai, Guizhou, 564507, China
| | - Jin-Ren Wu
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China
| | - Bo-Chen Liu
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China
| | - Xue-Lei Xu
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China
| | - Yu-Lin Fang
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China; Heyang Viti-viniculture Station, Northwest A & F University, Yangling, 712100, Shaanxi, China.
| | - Yan-Lun Ju
- College of Enology, Northwest A & F University, Yangling, 712100, Shaanxi, China.
| |
Collapse
|
17
|
Wang HF, Zhang YL, Liu XL, Zhu HL, Liang R, Liu BC, Zhou L, Meng L, Li WM, Jiang Q. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:535-542. [PMID: 34455739 PMCID: PMC8408488 DOI: 10.3760/cma.j.issn.0253-2727.2021.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
目的 调查中国慢性髓性白血病(CML)患者的治疗现状。 方法 横断面研究,2020年4月末至5月中旬,以填写调研问卷的形式在全国范围内调研CML患者,分析酪氨酸激酶抑制剂(TKI)一线选择、目前用药、药物转换和获得主要分子学反应(MMR)的比例及其影响因素。 结果 2933份来自全国31个省市自治区CML受访者的问卷可供分析,男性1683例(57.4%),中位年龄38(16~87)岁。一线选择:伊马替尼2481例(84.6%),原创性新药(原研药)1803例(61.5%)。填写问卷时用药:伊马替尼1765例(60.2%),原研药1791例(61.1%)。共1185例(40.4%)受访者曾经历TKI药物转换。1944例初发慢性期受访者TKI中位治疗45(3~227)个月,1417例(72.9%)获得≥MMR的疗效。多因素分析显示,城镇户籍(OR=0.6,95%CI 0.5~0.8,P<0.001)、≥大学学历(OR=0.5,95%CI 0.4~0.7,P<0.001)和进展期(OR=0.5,95%CI 0.3~0.8,P=0.001)受访者更少首选仿制TKI,而来自中部地区受访者比东部地区更多首选国产仿制TKI(OR=1.7,95%CI 1.4~2.0,P<0.001)。进展期受访者更多首选二代TKI(OR=5.4,95%CI 3.6~8.2,P<0.001),≥60岁受访者更少首选二代TKI(OR=0.4,95%CI 0.2~0.7,P=0.002)。诊断时处于进展期(OR=2.2,95%CI 1.6~3.2,P<0.001)、首选伊马替尼(OR=2.0,95%CI 1.6~2.6,P<0.001)、首选国产仿制药(OR=1.3,95%CI 1.1~1.6,P=0.002)、诊断距开始TKI治疗的时间更长(OR=1.2,95%CI 1.1~1.2,P<0.001)和服用TKI的时间更长(OR=1.1,95%CI 1.0~1.1,P<0.001)与药物转换比例增高显著相关。城镇户籍(OR=0.7,95%CI 0.6~0.8,P<0.001)、获≥MMR(OR=0.6,95%CI 0.5~0.8,P<0.001)和疗效未知(OR=0.7,95%CI 0.6~0.9,P=0.003)与药物转换比例低显著相关。女性(OR=1.4,95%CI 1.1~1.7,P=0.003)、城镇户籍(OR=1.6,95%CI 1.3~2.0,P<0.001)、初始服用伊马替尼(OR=1.4,95%CI 1.1~1.9,P=0.016)和TKI治疗时间更长(OR=1.2,95%CI 1.2~1.3,P<0.001)与获得≥MMR显著相关,而年龄≥60岁(OR=0.7,95%CI 0.4~1.0,P=0.047)和药物转换(OR=0.6,95%CI 0.5~0.7,P<0.001)与未获得MMR显著相关。 结论 截至2020年,中国CML患者中大多数首选并持续服用伊马替尼,半数以上服用原研药。社会人口学特征和疾病分期影响了患者的TKI选择、药物转换和治疗反应。
Collapse
Affiliation(s)
- H F Wang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Y L Zhang
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Tumor Hospital, Zhengzhou 450008, China
| | - X L Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - H L Zhu
- Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China
| | - R Liang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 510370, China
| | - B C Liu
- Institute of Hematology, Chinese Academy of Medical Science, Tianjin 300020, China
| | - L Zhou
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - L Meng
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - W M Li
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Q Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| |
Collapse
|
18
|
Zhang GJ, Gong XY, Qiu SW, Zhou CL, Liu KQ, Lin D, Liu BC, Wei H, Wei SN, Li Y, Gu RX, Gong BF, Liu YT, Fang QY, Mi YC, Wang Y, Wang JX. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center]. Zhonghua Xue Ye Xue Za Zhi 2021; 42:109-115. [PMID: 33858040 PMCID: PMC8071668 DOI: 10.3760/cma.j.issn.0253-2727.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
目的 评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病(Ph+ ALL)患者中的疗效及安全性。 方法 前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病医院收治的30例初诊成人Ph+ ALL患者入组。采用多药化疗方案,标准诱导化疗为期4周,自诱导化疗第8天开始口服达沙替尼(商品名依尼舒,正大天晴药业集团股份有限公司产品)100 mg/d,持续应用至整体治疗结束。有条件和意愿进行移植者,可进行异基因造血干细胞移植或自体造血干细胞移植。 结果 所有30例患者在诱导治疗4周后均达到血液学完全缓解(HCR),累积完全分子学反应(MCR)率为70.0%(21/30)。中位随访时间为37.8(32.0~46.6)个月。3年总生存(OS)率为68.1%,3年无血液学复发生存(HRFS)率为61.6%。63.3%的患者在治疗3个月时达到主要分子学反应(MMR)(其中有43.3%患者达到MCR)。6个月时60.0%的患者达到MCR,达到MCR的患者具有更好的OS(P=0.004)、HRFS(P=0.049)和EFS(P=0.001)。15例(50.0%)患者在第1次HCR期内进行移植,移植组患者HRFS(P=0.030)和EFS(P=0.010)优于化疗组。 结论 达沙替尼联合多药化疗方案治疗初诊Ph+ALL安全有效。 临床试验注册 ClinicalTrials.gov,NCT02523976。
Collapse
Affiliation(s)
- G J Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - X Y Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S W Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - C L Zhou
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - K Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D Lin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B C Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - H Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S N Wei
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R X Gu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B F Gong
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y T Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Q Y Fang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y C Mi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J X Wang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
19
|
Mei CL, Chen XN, Hao CM, Hu Z, Jiang HL, Li GS, Liu BC, Liu H, Liu ZS, Xing CY, Yao L, Yu C, Yuan WJ, Zuo L. [Development of a hyperkalemia risk assessment model for patients with chronic kidney disease]. Zhonghua Yi Xue Za Zhi 2020; 100:3498-3503. [PMID: 33256291 DOI: 10.3760/cma.j.cn112137-20200904-02561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Objective: To investigate risk factors for hyperkalemia among chronic kidney disease (CKD) patients and establish a risk assessment model for predicting hyperkalemia events. Methods: Clinical data of CKD patients (stage 3 to 5) hospitalized between May 2017 and June 2020 from 14 hospitals were retrospectively collected and divided into training dataset and validation dataset through balanced random sampling. Multivariate logistic regression analysis was used to analyze risk factors for hyperkalemia in CKD patients and the factors were scored. Receiver operating characteristic (ROC) curve was plotted and the area under the curve (AUC) was calculated. Meanwhile, the cut-off value with the best sensitivity and specificity were used to verify the accuracy of the model in validation dataset. Results: A total of 847 CKD patients were enrolled and further divided into training dataset (n=675) and validation dataset (n=172). There were 555 males and 292 females, with a mean age of (57.2±15.6) years. Multivariate logistic regression analysis showed that age, CKD stage, history of heart failure, history of serum potassium ≥5.0 mmol/L, diabetes, metabolic acidosis, and use of medications that increase serum potassium levels were risk factors for causing hyperkalemia in patients with CKD. Risk assessment model was established based on these risk factors. The AUC of the ROC curve was 0.809. Using 4 as the cut-off value, the sensitivity and specificity for predicting hyperkalemia events reached 87.1% and 57.0%, respectively. Conclusion: The model established in the current study can be used for predicting hyperkalemia events in clinical practices, which offers a new way to optimize serum potassium management in patients with CKD.
Collapse
Affiliation(s)
- C L Mei
- Department of Nephrology, Changzheng Hospital, Shanghai 200003, China
| | - X N Chen
- Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - C M Hao
- Department of Nephrology, Huashan Hospital Affiliated to Fudan University, Shanghai 200041, China
| | - Z Hu
- Department of Nephrology, Qilu Hospital, Shandong University, Jinan 250012, China
| | - H L Jiang
- Department of Blood Purification, the First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China
| | - G S Li
- Department of Nephrology, Sichuan Provincial People's Hospital, Chengdu 610072, China
| | - B C Liu
- Department of Nephrology, Zhongda Hospital Affiliated to Southeast University, Nanjing 210009, China
| | - H Liu
- Department of Nephrology, the Second Xiangya Hospital of Central South University, Changsha 410001, China
| | - Z S Liu
- Department of Nephropathy Rheumatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - C Y Xing
- Department of Nephrology, Jiangsu Provincial People's Hospital, Nanjing 210029, China
| | - L Yao
- Department of Nephrology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China
| | - C Yu
- Department of Nephrology, Tongji Hospital, Tongji University, Shanghai 200065, China
| | - W J Yuan
- Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
| | - L Zuo
- Department of Nephrology, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
20
|
Zheng FY, Zhang Y, Zhang LQ, Liu BC, Meng L, Jin J, Liu HL, Sun ZM, Lin LE, Lei PC, Zhu XF, Ma HX, Lu ZS, Jiang H, Zhao YH, Lin H, Zhang X, Yang GP, Zhu HL, Chen SN, You Y, Li WM, Bai QX, Zhao XL, Li ZY, Shen XM, Zhang LP, Jiang Q. [Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:545-551. [PMID: 32810960 PMCID: PMC7449767 DOI: 10.3760/cma.j.issn.0253-2727.2020.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
目的 评估伊马替尼对慢性髓性白血病慢性期(CML-CP)儿童身高的影响。 方法 2018年7月至2019年7月,在全国范围内对诊断时年龄<18周岁、接受伊马替尼治疗至少3个月的CML儿童或其家长发放问卷,调查受访者伊马替尼治疗前后身高的变化。主要评价指标为身高标准差积分值(HtSDS)以及标准差积分的差值(ΔHtSDS),并分析其相关影响因素。 结果 共有238例受访者符合标准并被纳入研究,男性138例(58.0%),初诊时中位年龄11.0(1.4~17.9)岁,青春期前93例(39.0%),至填写答卷时,中位年龄15.0(2.0~34.0)岁,中位伊马替尼服药时间28(3~213)个月。受访者填写答卷时HtSDS(−0.063±1.361)较治疗前HtSDS(0.391±1.244)显著下降(P<0.001),71.0%的患儿出现身高增长减慢。青春期前服药者治疗后HtSDS下降显著(P<0.05),而青春期开始后服药者HtSDS变化不明显(P>0.05)。多因素分析显示,服药初始年龄较小(偏回归系数为0.122,B=0.572,t=10.733,P<0.001)和服药时间较长(偏回归系数为−0.006,B=−0.211,t=−4.062,P<0.001)是伊马替尼抑制身高增长的独立影响因素。 结论 伊马替尼引起CML-CP儿童身高增长障碍,服药初始年龄越小、服药时间越长,伊马替尼对身高的影响越明显。
Collapse
Affiliation(s)
- F Y Zheng
- Peking University People's Hospital, Beijing 100044, China
| | - Yanli Zhang
- Henan Cancer Hospital, Zhengzhou 450008, China
| | - L Q Zhang
- Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China
| | - B C Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - L Meng
- Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430030, China
| | - J Jin
- The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou 310003, China
| | - H L Liu
- Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China
| | - Z M Sun
- Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China
| | - L E Lin
- Hainan General Hospital, Haikou 570311, China
| | - P C Lei
- Henan Provincial People's Hospital, Zhengzhou 450003, China
| | - X F Zhu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | - H X Ma
- The Third Hospital of Zhengzhou, Zhengzhou 450003, China
| | - Z S Lu
- Guangdong General Hospital, Guangzhou 510080, China
| | - H Jiang
- Guangzhou Women and Children's Medical Center, Guangzhou 510623, China
| | - Y H Zhao
- The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
| | - H Lin
- Jilin University First Hospital, Changchun 130021, China
| | - X Zhang
- Maoming People's Hospital, Maoming 525000, China
| | - G P Yang
- The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - H L Zhu
- West China Hospital of Sichuan University, Chengdu 610041, China
| | - S N Chen
- The First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Y You
- Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430022, China
| | - W M Li
- Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430022, China
| | - Q X Bai
- Xijing Hospital of Air Force Medical University, Xi'an 710032, China
| | - X L Zhao
- Xiangya Hospital of Central South University, Changsha 410008, China
| | - Z Y Li
- Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China
| | - X M Shen
- The First People's Hospital of Yunnan Province, Kunming 650034, China
| | - L P Zhang
- Peking University People's Hospital, Beijing 100044, China
| | - Q Jiang
- Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
21
|
Li Y, Gong XY, Zhao XL, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Wang HJ, Li CW, Li QH, Gong BF, Liu YT, Wei SN, Zhang GJ, Mi YC, Wang JX, Liu KQ. [Rituximab combined with short-course and intensive regimen for Burkitt leukemia: efficacy and safety analysis]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:502-505. [PMID: 32654465 PMCID: PMC7378285 DOI: 10.3760/cma.j.issn.0253-2727.2020.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
目的 探讨利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病患者的疗效和安全性。 方法 收集2006年1月30日至2018年9月12日中国医学科学院血液病医院收治的11例Burkitt白血病患者病例资料,分析统计患者的临床特征、完全缓解(CR)率、总生存率、无复发生存率及不良事件。 结果 11例患者中位年龄34(15~54)岁,其中男6例,女5例。发病时中位WBC 12.28(2.21~48.46)×109/L,HGB 113(74~147)g/L,PLT 35(13~172)×109/L,乳酸脱氢酶2 721(803~17 370)U/L,外周血中位原始细胞比例0.40(0.03~0.76),骨髓中位原始细胞比例0.840(0.295~0.945)。10例患者接受利妥昔单抗联合短疗程、高强度化疗,其中2例患者巩固化疗后行自体造血干细胞移植。所有治疗患者1个疗程CR率为100%,4年总生存率为90%,4年无复发生存率为90%。所有治疗患者中,只有1例患者在诱导化疗中出现肿瘤溶解综合征,经血液透析等治疗后肾功能恢复。无治疗相关性死亡病例。 结论 利妥昔单抗联合短疗程、高强度方案治疗成人Burkitt白血病疗效及安全性均较为理想。
Collapse
Affiliation(s)
- Y Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X Y Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - X L Zhao
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - D Lin
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C L Zhou
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B C Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H J Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - C W Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Q H Li
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B F Gong
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y T Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - S N Wei
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - G J Zhang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y C Mi
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - J X Wang
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - K Q Liu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; State Key Laboratory of Experimental Hematology; National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| |
Collapse
|
22
|
Wang XY, Ding WW, Liu BC, Sun SL, Fan XX, Wu XJ, Li JS. [Relative factors of transmural intestinal necrosis in acute superior mesenteric vein thrombosis]. Zhonghua Wai Ke Za Zhi 2019; 57:44-50. [PMID: 31510732 DOI: 10.3760/cma.j.issn.0529-5815.2019.10.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To examine the relative factors of transmural intestinal necrosis (TIN) during multidisciplinary stepwise management facilitating the decision making in patients with acute superior mesenteric vein thrombosis (ASMVT). Methods: Clinical data of patients with ASMVT admitted to Department of General Surgery, Jinling Hospital from January 2009 to June 2017 were reviewed retrospectively. There were 52 males and 37 females, aging (45.9 ± 12.6) years (range: 20 to 69 years). According to the postoperative pathological results and follow-up, the patients were divided into TIN group (n=31) and non-TIN group (n=58, including 18 cases of intestinal stricture). The related factors were compared between ASMVT patients with TIN and patients without TIN by univariate analysis using t test, U test and χ(2) test accordingly, and factors with statistically significance were subsequently submitted to binary Logistic regression analysis. The predictive value and cut-off point of factors were evaluated by receiver operator characteristic (ROC) curve and area under the curve. Results: In univariate analysis, smoking, hypertension, peritonitis, white blood cell count,haemoglobin, international normalized ratio, blood albumin, thrombosis of superior mesenteric branches vein, free intraperitoneal fluid, decrease of bowel wall enhancement and pneumatosis intestinalis were TIN risk factors (all P<0.05). According to the binary Logistic regression analysis, white blood cell count (OR=1.093, 95%CI: 1.010 to 1.182, P=0.027), thrombosis of the superior mesenteric branches vein (OR=11.519, 95%CI: 1.906 to 69.615, P=0.008), pneumatosis intestinalis (OR=11.140, 95%CI: 2.360 to 52.585, P=0.002) were independent relative factors of TIN in patients with AMI, and the area under the ROC curve of the above factors and predictive model was 0.759 (95%CI: 0.647 to 0.871), 0.745 (95%CI: 0.641 to 0.848), 0.737 (95%CI: 0.621 to 0.854), 0.909 (95%CI: 0.847 to 0.971), respectively. The cutoff value of white blood cell count was 18.1 × 10(9)/L. Conclusion: White blood cell levels, superior mesenteric vein branch thrombosis and pneumatosis intestinalis are independent predictors of TIN in ASMVT.
Collapse
Affiliation(s)
- X Y Wang
- Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Research Institute of General Surgery of People's Liberation Army, Nanjing 210002, China
| | | | | | | | | | | | | |
Collapse
|
23
|
Liu KQ, Wang Y, Zhao Z, Lin D, Zhou CL, Liu BC, Gong XY, Zhao XL, Wei SN, Zhang GJ, Gong BF, Li Y, Liu YT, Mi YC, Wang JX, Wei H. [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:497-501. [PMID: 31340623 PMCID: PMC7342402 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
目的 比较初诊急性髓系白血病(AML)患者诱导化疗后骨髓抑制期应用聚乙二醇化重组人G-CSF(PEG-rhG-CSF)与普通重组人G-CSF(rhG-CSF)促进中性粒细胞或白细胞恢复的时间。同时比较两种药物对患者感染发生率、住院时间的影响。 方法 采用前瞻性随机对照研究方法,将2014年8月至2017年12月间符合入组条件的初诊AML患者诱导治疗后按1∶1比例随机分成两组:PEG-rhG-CSF组和rhG-CSF组。对比分析两组患者中性粒细胞计数(ANC)或WBC恢复时间、感染发生率和住院时间。 结果 共入组初诊AML患者60例,PEG-rhG-CSF组30例,rhG-CSF组30例。两组患者除性别构成外,在年龄、化疗方案、化疗前ANC、WBC、诱导化疗疗效方面差异均无统计学意义(P值均>0.05)。PEG-rhG-CSF组患者与rhG-CSF组患者的ANC、WBC恢复中位时间分别为19(14~35)d、19(15~26)d,差异无统计学意义(t=0.580,P=0.566)。PEG-rhG-CSF组、rhG-CSF组患者骨髓抑制期感染的发生率分别为90.0%、93.3%,差异无统计学意义(P=1.000)。两组患者的中位住院时间分别为20.5(17~49)d、21(19~43)d,差异无统计学意义(P=0.530)。 结论 AML患者诱导治疗后应用PEG-rhG-CSF与rhG-CSF无论在ANC或WBC恢复时间,还是在感染的发生率及住院时间均相当。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Affiliation(s)
- D Yang
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - B C Liu
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - J Luo
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - T X Huang
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| | - C T Liu
- Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, China
| |
Collapse
|
25
|
Liu KQ, Wei H, Lin D, Wang Y, Zhou CL, Liu BC, Li XL, Zhao Y, Li HJ, Wang CW, Li QH, Li BF, Gong YT, Liu XY, Gong YC, Mi JX, Wang J. [Clinical significance of minimal residual disease in patients with Ph-negative precursor B-acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:724-728. [PMID: 30369181 PMCID: PMC7342254 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
目的 探讨微小残留病(MRD)水平在Ph染色体阴性的急性B淋巴细胞白血病(Ph− B-ALL)中的预后意义。 方法 采用多色流式细胞术对2010年9月至2017年11月初诊的193例Ph− B-ALL患者在治疗后1、3、6个月进行骨髓MRD监测,并对不同MRD水平患者的预后进行比较。 结果 中位随访22(1~92)个月,所有193例患者共行497次MRD检测。1个月时MRD水平<0.1%和≥0.1%患者的3年预期无复发生存(RFS)率分别为74.5%和29.9%,3年预期总生存(OS)率分别为67.5%和30.3%;3个月时MRD水平阴性和阳性患者的3年预期RFS率分别为75.6%和29.7%,3年预期OS率分别为71.6%和27.8%;6个月时MRD水平阴性或阳性患者的3年预期RFS率分别为74.6%和11.6%,3年预期OS率分别为74.0%和15.7%,差异均有统计学意义(P值均<0.001)。3个监测点全部达到MRD阴性标准的患者与至少1次未达到MRD阴性标准的患者比较,3年预期RFS、OS率差异均有统计学意义(80.5%对30.5%,77.1%对29.4%,P值均<0.001)。多因素分析结果显示,3个月时的MRD水平是Ph− B-ALL患者独立的预后因素之一。 结论 治疗后MRD监测对Ph− B-ALL的预后判断有重要意义。
Collapse
Affiliation(s)
- K Q Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Gu RX, Wei H, Wang Y, Liu BC, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Gong XY, Li Y, Qiu SW, Mi YC, Wang JX. [Impact of duration of antibiotic therapy on the prognosis of patients with acute myeloid leukemia who had Gram-negative bloodstream infection in consolidation chemotherapy]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:471-475. [PMID: 30032562 PMCID: PMC7342929 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
目的 分析巩固化疗期间伴发革兰阴性菌(G−菌)血流感染的急性髓系白血病(AML)患者抗感染疗程对感染转归的影响。 方法 回顾性分析2010年9月至2016年1月入组“依据危险度分层对急性髓系白血病优化治疗的研究”临床试验的591例AML(非急性早幼粒细胞白血病)患者的血流感染资料,将其中巩固化疗期间发生G−菌血流感染且持续发热时间<7 d的114例次血流感染(89例患者)纳入研究,分析抗感染疗程对感染转归的影响。 结果 114例次血流感染发生时,患者中位ANC为0(0~5.62)×109/L,中性粒细胞缺乏(粒缺)持续的中位时间为9(3~26)d,抗感染治疗的中位时间为7(4~14)d。抗感染疗程≤7 d与>7 d组比较,停药后3 d内再发热比例、再次发生相同菌株血流感染比例分别为1.2%对3.0%、18.5%对21.2%,差异均无统计学意义(P=0.522,OR=0.400,95%CI 0.024~6.591;P=0.741,OR=0.844,95%CI 0.309~2.307)。同时,两组患者均未发生7 d及30 d内感染相关死亡。且倾向性评分平衡患者特征及用药差异因素后,抗感染疗程≤7 d较>7 d组再次发生相同菌株血流感染比例仍无明显增高(P=0.525,OR=0.663,95%CI 0.187~2.352)。 结论 对于巩固化疗期间伴发G−菌血流感染的AML患者,若发热时间<7 d,敏感抗菌药物治疗7 d后停药并不增加停药后3 d内再发热,粒缺期再次出现相同菌株血流感染及感染相关7 d、30 d内死亡风险。提示短疗程抗感染方案可以成为巩固化疗伴发G−菌血流感染AML患者感染控制情况下合理的治疗选择。
Collapse
Affiliation(s)
- R X Gu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Zhu XJ, You Y, Duan MH, Zhu Y, Liu BC, Chen SN, Du X. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China]. Zhonghua Xue Ye Xue Za Zhi 2019; 39:994-997. [PMID: 30612400 PMCID: PMC7348222 DOI: 10.3760/cma.j.issn.0253-2727.2018.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
目的 回顾性分析中国慢性髓性白血病(CML)酪氨酸激酶抑制剂(TKI)自动停药患者的临床特征及转归情况。 方法 回顾性分析2005年6月1日至2018年3月1日国内7家单位109例自动停用TKI的慢性期CML患者临床资料,将其中具有明确停药结局及相对完整临床资料的91例患者进行统计分析,观察患者自动停药后获得无治疗缓解(TFR)情况及其影响因素。 结果 91例患者累积服用TKI中位时间为65(7~138)个月,其中21例患者有减停药史;患者达到主要分子学缓解(MMR)中位时间为开始服用TKI后6(3~57)个月;全部患者停药前达MR4.0。停药后中位随访9(1~72)个月,53例(58.2%)患者继续维持MMR,获得TFR;38例(41.8%)失去MMR。12个月和25个月的TFR率分别为61.4%和52.6%。31例停药后复发的患者再启动药物治疗,用药后再获得MMR的中位时间为3(1~12)个月。对比分析发现,Sokal评分(P=0.294)、累积服用TKI时间(P=0.827)、获得MMR所需时间(P=0.553),是否减停TKI(P=0.125)等因素对复发无明显影响。而停药前MMR维持时间越长(≥24个月)患者后期复发率越低(P=0.027)。 结论 达停药标准的中国CML患者能够安全停用TKI,停药后TFR率与国外报道相当。停药前MMR时间维持越长,停药后复发率越低。
Collapse
Affiliation(s)
| | | | | | | | | | - S N Chen
- First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - X Du
- the Second People's Hospital of Shenzhen, Shenzhen 518035, China
| |
Collapse
|
28
|
Gong BF, Liu YT, Zhang GJ, Wei SN, Li Y, Liu KQ, Gong XY, Zhao XL, Qiu SW, Gu RX, Lin D, Wei H, Zhou CL, Liu BC, Wang Y, Mi YC, Wang JX. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi 2018; 38:528-531. [PMID: 28655098 PMCID: PMC7342978 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the incidence of invasive fungal infections (IFI) and usage of intravenous antifungal drugs during remission induction chemotherapy in patients with acute myeloid leukemia (AML) under primary antifungal prophylaxis with posaconazole. Methods: Clinical records from newly diagnosed AML patients above 15 years old in one single center from February 2014 to January 2016 were retrospectively reviewed and analyzed, excluding acute promyelocytic leukemia. The incidence of IFI and usage of intravenous antifungal drugs were investigated between control group (not receiving any broad spectrum antifungal prophylaxis) and treatment group (receiving posaconazole as primary prophylaxis). Results: A total of 147 newly diagnosed AML patients were enrolled. Of them, 81 received prophylaxis with posaconazole, and 66 did not receive broad-spectrum antifungal treatment. 7 IFI occurred in posaconazole group, and all were possible cases; 19 IFI occurred in control group (3 proven, 4 probable, 12 possible). The incidence of IFI was significantly lower in treatment group than that in control group (8.6% vs 28.8%, χ(2)=10.138, P=0.001). Usage of intravenous antifungal drugs was significantly decreased in posaconazole group (18.5% vs 50.0%, χ(2)=16.390, P<0.001). Conclusion: Prophylaxis with posaconazole coulf prevent IFI and reduce usage of intravenous antifungal drugs significantly during remission induction chemotherapy in AML patients.
Collapse
Affiliation(s)
- B F Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Wan YL, Wang Y, Liu BC, Liu X, Gong XY, Zhao XL, Wang TY, Jiang EL, Feng SZ, Han MZ, Qiu LG, Mi YC, Wang JX. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world]. Zhonghua Xue Ye Xue Za Zhi 2018; 37:886-891. [PMID: 27801322 PMCID: PMC7364881 DOI: 10.3760/cma.j.issn.0253-2727.2016.10.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
目的 探讨真实世界中伊马替尼(IM)联合化疗治疗BCR-ABL阳性急性淋巴细胞白血病(ALL)的疗效及相关预后因素。 方法 2003年4月至2015年8月收治的209例治疗中包含IM的BCR-ABL阳性ALL患者纳入研究,106例患者接受造血干细胞移植(HSCT)。对患者的疗效和预后影响因素进行分析。 结果 初诊患者诱导完全缓解(CR)率为97.9%。初诊时WBC≥100×109/L是总生存(OS)的不良预后因素(P=0.043)。未接受HSCT、诱导治疗4周内未达CR和治疗过程中未达到分子生物学完全缓解(CMR)是OS(P值分别为<0.001、0.009和<0.001)和无复发生存(RFS)(P值均<0.001)的不良预后因素。接受异基因HSCT和自体HSCT的患者,其OS和RFS的差异均无统计学意义(P值均>0.05)。首次诱导治疗时联用IM的患者较未联用者显示出更高的5年RFS率(37.0%对24.0%,P= 0.005)。在治疗过程中持续规律服用酪氨酸激酶抑制剂(TKI,40例患者由于复发、转录本水平下降不理想或出现突变换用其他TKI)的患者生存情况最佳,其次为骨髓抑制期间断停用TKI的患者,不规律服用TKI的患者生存情况最差,三组5年OS率分别为46.0%、28.0%、17.0%(P=0.004),5年RFS率分别为38.0%、28.0%、17.0%(P<0.001)。 结论 TKI联合化疗获得CMR,序贯以HSCT可改善BCR-ABL阳性ALL患者预后,持续规律地联用TKI有助于BCR-ABL阳性ALL患者疗效的提高。
Collapse
Affiliation(s)
- Y L Wan
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, Zhao JW, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi 2018; 39:9-14. [PMID: 29551026 PMCID: PMC7343107 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 01/27/2023]
Abstract
Objective: To analyze the clinical and laboratory characteristics, and prognosis of adult acute myeloid leukemia (AML) patients with MLL gene rearrangements. Methods: The medical records of 92 adult AML patients with MLL gene rearrangements from January 2010 to December 2016 were retrospectively analyzed. Results: 92 cases (6.5%) with MLL gene rearrangements were identified in 1 417 adult AML (Non-M(3)) patients, the median age of the patients was 35.5 years (15 to 64 years old) with an equal sex ratio, the median WBC were 21.00(0.42-404.76)×10(9)/L, and 78 patients (84.8%) were acute monoblastic leukemia according to FAB classification. Eleven common partner genes were detected in 32 patients, 9 cases (28.1%) were MLL/AF9(+), 5 cases (15.6%) were MLL/AF6(+), 5 cases (15.6%) were MLL/ELL(+), 2 cases (6.3%) were MLL/AF10(+), 1 case (3.1%) was MLL/SETP6(+), and the remaining 10 patients' partner genes weren't identified. Of 92 patients, 83 cases with a median follow-up of 10.3 (0.3-74.0) months were included for the prognosis analysis, the complete remission (CR) rate was 85.5% (71/83), the median overall survival (OS) and relapse free survival (RFS) were 15.4 and 13.1 months, respectively. Two-year OS and RFS were 36.6% and 29.5%, respectively. Of 31 patients underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT), two-year OS and RFS for patients received and non-received allo-HSCT were 57.9% and 21.4%, 52.7% and 14.9%, respectively (P<0.001). Among patients with partner genes tested, 9 of 32 cases (28.1%) were MLL/AF9(+), the median follow-up was 6.0(4.1-20.7) months. 3 patients with MLL/AF9 underwent allo-HSCT. 23 cases (71.9%) were non- MLL/AF9(+), the median follow-up was 7.8 (0.3-26.6) months. 14 patients (60.1%) with non-MLL/AF9 underwent allo-HSCT. One-year OS for patients with MLL/AF9 and non-MLL/AF9 were 38.1% and 55.5%, respectively (P=0.688). Multivariate analysis revealed that high WBC (RR=1.825, 95% CI 1.022-3.259, P=0.042), one cycle to achieve CR (RR=0.130, 95% CI 0.063-0.267, P<0.001), post-remission treatment with allo-HSCT (RR=0.169, 95% CI 0.079-0.362, P<0.001) were independent prognostic factors affecting OS. Conclusions: AML with MLL gene rearrangements was closely associated with monocytic differentiation, and MLL/AF9 was the most frequent partner gene. Conventional chemotherapy produced a high response rate, but likely to relapse, allo-HSCT may have the potential to further improve the prognosis of this group of patients.
Collapse
Affiliation(s)
- X Y Gong
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Cheng YS, Chao J, Zhu DD, Liu BC. 14 The mechanism of pkcΒ-p66shc-nadph oxidase pathway in high glucose induced-oxidative stress in renal tubular epithelial cells. J Investig Med 2017. [DOI: 10.1136/jim-2017-mebabstracts.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Peng N, Wei H, Lin D, Zhou CL, Liu BC, Wang Y, Liu KQ, Gong BF, Wei SN, Zhang GJ, Liu YT, Gong XY, Qiu SW, Mi YC, Wang JX. [Prognostic significance of flow cytometric minimal residual disease in acute myeloid leukemia during aplasia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:767-771. [PMID: 29081193 PMCID: PMC7348354 DOI: 10.3760/cma.j.issn.0253-2727.2017.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Indexed: 11/16/2022]
Abstract
Objective: To investigate the impact of minimal residual disease (MRD) by multiparameter flow cytometry (MPFC) during aplasia on efficacy and prognosis of de novo acute myeloid leukemia (AML) (non M(3)) patients. Methods: The MRD data by 8-color MPFC during aplasia (day 14-15 of induction therapy) in 85 de novo AML (non M(3)) patients and the MRD impact on efficacy and prognosis were retrospectively analyzed. Results: Data of 85 patients, including 42 males (49.4%) and 43 females (50.6%) , were collected, with a median age of 35 (15-54) years. The median MRD by MPFC during aplasia was 0.58% (0-81.11%) , and 70 (82.4%) patients achieved complete remission (CR) after first induction chemotherapy. The cutoff of MRD by receiver operating characteristic (ROC) analysis was 2.305% (Se= 0.867, Sp=0.800) . The CR rate after one course was significantly higher in patients with MRD<2.305% [96.6% (56/58) ]than in patients with MRD≥2.305%[51.9% (14/27) ] (χ(2)=22.348, P<0.001) ; no significant difference with respect to relapse-free survival rate (χ(2)=1.08, P=0.299) or overall survival rate (χ(2)=0.42, P=0.516) could be demonstrated for the comparison of the two groups. Multivariates analysis showed MRD divided by 2.305% was the only independent prognostic factor for CR after one course (OR= 21.560, 95% CI 4.129-112.579, P<0.001) . Conclusion: Flow cytometric MRD divided by 2.305% during aplasia could be a predictor of efficacy after first induction therapy in AML patients.
Collapse
Affiliation(s)
- N Peng
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Zhao N, Wei H, Wang Y, Lin D, Zhou CL, Liu BC, Liu KQ, Zhang GJ, Wei SN, Gong BF, Gong XY, Li W, Li Y, Liu YT, Qiu SW, Gu RX, Mi YC, Wang JX. [Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:695-699. [PMID: 28954349 PMCID: PMC7348239 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Indexed: 11/14/2022]
Abstract
Objective: To probe the potential utility of Wilms tumor 1 (WT1) as a marker of minimal residual disease (MRD) in acute myeloid leukemia (AML) to estimate the relapse-predicting cut-off value. Methods: Quantitative assessment of bone marrow WT1 mRNA level was preformed using real-time quantitative reverse transcription polymerase chain reaction (RQ-RT-PCR) assay. The expression levels of WT1 dynamically measured with RQ-RT-PCR were retrospectively analyzed in 121 AML cases (not including acute promyelocytic leukemia) achieving complete remission (CR) after induction therapy followed by consolidation therapy. By comparing WT1 levels of patients with different post-therapy outcomes, the investigators used the receiver operating characteristic (ROC) curve to determine WT1 threshold so as to predict their clinical relapses. Then prognoses and the significance of intervention were analyzed between WT1 positive and negative patients according to the cut-off value of WT1. Results: According to ROC curve, WT1 level higher than 2.98% predicted the possibility of relapse. For simplicity and clinical application, 3.00% was used as the cut-off value of WT1 level for relapse. WT1 levels in 41 patients at diagnosis were detected, meanwhile 3 patients whose WT1 levels at diagnosis below 3.00% were excluded, then the median WT1 level of the rest 38 patients at diagnosis was 44.09% (range 7.19%-188.06%) . The median WT1 level in remission was 0.48% (352 samples, range 0-8.41%) . The median WT1 level at diagnosis was higher than that in remission. Excluding the 3 patients with WT1 level at diagnosis under 3.00%, the relapse rate of WT1 positive group (>3.00% during consolidation phase and follow-up) and WT1 negative group (≤3.00%) was 70.0% (14/20) and 12.2% (12/98) respectively (P<0.001) . The median time from WT1 positivity to clinical relapse was 58 days. Conclusions: WT1 expression level above 3.00% was associated with markedly high risk of relapse, which could be as a useful marker for monitoring MRD following consolidation therapy.
Collapse
Affiliation(s)
- N Zhao
- Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Pan MM, Liu BC. [Hypoxia-inducible factors stabilizer: new approach for treatment of renal anemia]. Zhonghua Nei Ke Za Zhi 2017; 56:225-228. [PMID: 28253609 DOI: 10.3760/cma.j.issn.0578-1426.2017.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
35
|
Gong XY, Wang Y, Liu BC, Wei H, Zhou CL, Lin D, Liu KQ, Wei SN, Gong BF, Zhang GJ, Liu YT, Zhao XL, Li Y, Gu RX, Qiu SW, Mi YC, Wang JX. [Clinical features and prognosis in CD10(-) pre-B acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:17-21. [PMID: 28219219 PMCID: PMC7348396 DOI: 10.3760/cma.j.issn.0253-2727.2017.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
目的 分析CD10阴性的前B急性淋巴细胞白血病(CD10−pre B-ALL)患者的临床特征和预后。 方法 对6例成人CD10− pre B-ALL患者的临床和实验室资料进行回顾性分析,结合文献复习明确该类型患者的临床特征及预后。 结果 CD10−pre B-ALL占ALL的1.5%(6/409),占B-ALL的1.8%(6/343),占pre B-ALL的11.5%(6/52)。6例患者均为男性,中位年龄为33.5岁,起病时中位WBC为101.78×109/L,所有患者均伴有MLL-AF4融合基因表达。5例患者经1个疗程诱导化疗即获得完全缓解(CR),1例患者经3个疗程化疗后才获得CR。2例患者在CR1期行异基因造血干细胞移植(allo-HSCT),1例患者CR后短期内即复发,在CR2期行allo-HSCT。1例患者正在等待移植。2例未移植患者1例复发死亡,1例尚处于缓解状态。 结论 CD10−pre B-ALL是一类具有独特临床特征的成人ALL亚型,发生率较低,常见于男性,起病时白细胞水平较高,MLL-AF4融合基因表达率高,常规化疗具有较高的缓解率,但易复发,allo-HSCT有可能改善其预后。
Collapse
Affiliation(s)
- X Y Gong
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Liu BC, Tang TT, Lü LL. [Opportunities and challenges in the study of renal fibrosis in the era of precision medicine]. Zhonghua Yi Xue Za Zhi 2016; 96:3041-3043. [PMID: 27784442 DOI: 10.3760/cma.j.issn.0376-2491.2016.38.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
37
|
Wang Y, Liu BC, Wei H, Lin D, Zhou CL, Liu KQ, Li W, Wei SN, Wang JY, Gong BF, Zhang GJ, Zhao XL, Liu YT, Gong XY, Li Y, Gu RX, Mi YC, Wang JX. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial]. Zhonghua Xue Ye Xue Za Zhi 2016; 37:183-8. [PMID: 27033753 PMCID: PMC7342959 DOI: 10.3760/cma.j.issn.0253-2727.2016.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To compare the efficacy and toxicities of combining homoharringtonine (HHT)±daunorubicin (DNR) with all-trans-retinoic acid (ATRA) based therapy and DNR plus ATRA based therapy in newly diagnosed low/intermediate risk acute promyelocytic leukemia (APL). METHODS A total of 96 newly diagnosed patients with APL were randomized to HHT group, DNR group and HHT+ DNR group prospectively. The complete remission (CR) rate, the overall survival (OS) and event-free survival (EFS) of three groups were analyzed. RESULTS There were 31 patients in HHT group, 33 patients in DNR group and 32 patients in HHT+ DNR group. The baseline characteristics of three groups were similar. No patient died during induction therapy. The morphologic CR rate was 100.0%. The median time to peak WBC counts in HHT+DNR group (4 days, range: 1-23 days) was significantly shorter than that in HHT group (9 days, range: 1-27 days) (P=0.008) and DNR group (7 days, range: 1-27 days) (P=0.240). There was no difference among three groups about the incidence of differentiation syndrome, the median interval to achieve CR, peak WBC counts and transfusions (P >0.05). All patients achieved complete molecular remission (CMR) during consolidation therapy. The interval to achieve CMR was no significantly difference among three groups (P >0.05). The 3-year OS rates for HHT group, DNR group and HHT+DNR group were 95.0%, 100.0% and 91.0%, respectively (P=0.595). The 3-year EFS rates for three groups were 93.0%, 90.0% and 85.0% (P=0.382). No difference was found in the incidence of adverse events among three groups (P >0.05). CONCLUSIONS Similar to DNR plus ATRA based therapy, HHT plus ATRA based induction and consolidation therapy should be one of highly-efficient treatment options for newly diagnosed APL. Clinical trial registration Chinese Clinical Trial Registry, ChiCTR-TRC-12002628.
Collapse
Affiliation(s)
- Y Wang
- Leukemia Center, Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD. Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus 2013; 27:790-7. [PMID: 24147952 DOI: 10.1111/dote.12145] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The aim of this study was to evaluate the diagnostic values by detecting sera autoantibodies to eight tumor-associated antigens (TAAs) of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn and Koc full-length recombinant proteins for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma (ESCC). Enzyme-linked immunosorbent assay was used to detect autoantibodies against the eight selected TAAs in 567 sera samples from four groups, including 200 individuals with normal esophageal epithelia (NOR), 214 patients with esophageal basal cell hyperplasia (BCH), 65 patients with esophageal dysplasia (DYS), and 88 patients with ESCC. In addition, the expression of the eight antigens in esophageal tissues was analyzed by immunohistochemistry. Statistically significant distribution differences were identified among the four groups for each of the individual autoantibodies to six TAAs (P53, IMP1, P16, cyclin B1, P62, and C-myc); the detection rates of antoantibodies were positively correlated with the progression of ESCC. When autoantibody assay successively accumulated to six TAAs (P53, IMP1, P16, cyclin B1, P62, and C-myc), a stepwise increased detection frequency of autoantibodies was found in the four sera groups (6% in NOR, 18% in BCH, 38% in DYS, and 64% in ESCC, respectively), the risks to BHC, DYS, and ESCC steadily increased about 3-, 9-, and 27-folds. The sensitivity and the specificity for autoantibodies against the six TAAs in diagnosing ESCC reached up to 64% and 94%, respectively. The area under the receiver operating characteristic curve for the six anti-TAA autoantibodies was 0.78 (95% confidence interval 0.74-0.83). No more increasing in sensitivity was found with the addition of new anti-TAA autoantibodies. A combination detection of autoantibodies to TAAs might distinguish ESCC patients from normal individuals and the patients with esophageal precancerous lesions.
Collapse
Affiliation(s)
- S L Zhou
- Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Zheng Y, Su LN, Liu M, Liu BC, Shen ZW, Fan HT, Li YT, Chen LM, Lu X, Ma JL, Wang WM, Wang ZH, Wei ZY, Zhang J. Note: A new angle-resolved proton energy spectrometer. Rev Sci Instrum 2013; 84:096103. [PMID: 24089878 DOI: 10.1063/1.4820918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
In typical laser-driven proton acceleration experiments Thomson parabola proton spectrometers are used to measure the proton spectra with very small acceptance angle in specific directions. Stacks composed of CR-39 nuclear track detectors, imaging plates, or radiochromic films are used to measure the angular distributions of the proton beams, respectively. In this paper, a new proton spectrometer, which can measure the spectra and angular distributions simultaneously, has been designed. Proton acceleration experiments performed on the Xtreme light III laser system demonstrates that the spectrometer can give angle-resolved spectra with a large acceptance angle. This will be conductive to revealing the acceleration mechanisms, optimization, and applications of laser-driven proton beams.
Collapse
Affiliation(s)
- Y Zheng
- Beijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lin XX, Li YT, Liu F, Liu BC, Du F, Wang SJ, Chen LM, Zhang L, Zheng Y, Liu X, Liu XL, Wang ZH, Ma JL, Wei ZY, Zhang J. Note: Diagnosing femtosecond laser-solid interactions with monochromatic Kα imager and x-ray pinhole camera. Rev Sci Instrum 2011; 82:036104. [PMID: 21456806 DOI: 10.1063/1.3567014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
An x-ray pinhole camera and a monochromatic K(α) imager are used to measure the interactions of intense femtosecond laser pulses with Cu foil targets. The two diagnostics give different features in the spot size and the laser energy scaling, which are resulted from different physical processes. Under our experimental conditions, the K(α) emission is mainly excited by the fast electrons transporting inside the cold bulk target. In contrast, the x-ray pinhole signals are dominated by the broadband thermal x-ray emission from the hot plasma at the front target surface.
Collapse
Affiliation(s)
- X X Lin
- Beijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing 100190, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Lin XX, Li YT, Liu BC, Liu F, Du F, Wang SJ, Lu X, Chen LM, Zhang L, Liu X, Wang J, Liu F, Liu XL, Wang ZH, Ma JL, Wei ZY, Zhang J. Effect of prepulse on fast electron lateral transport at the target surface irradiated by intense femtosecond laser pulses. Phys Rev E 2011; 82:046401. [PMID: 21230399 DOI: 10.1103/physreve.82.046401] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2010] [Revised: 07/09/2010] [Indexed: 11/07/2022]
Abstract
The effects of preplasma on lateral fast electron transport at front target surface, irradiated by ultraintense (>10(18) W/cm2) laser pulses, are investigated by Kα imaging technique. A large annular Kα halo with a diameter of ∼560 μm surrounding a central spot is observed. A specially designed steplike target is used to identify the possible mechanisms. It is believed that the halos are mainly generated by the lateral diffusion of fast electrons due to the electrostatic and magnetic fields in the preplasma. This is illustrated by simulated electron trajectories using a numerical model.
Collapse
Affiliation(s)
- X X Lin
- Beijing National Laboratory for Condensed Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing 100190, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Yan XQ, Lin C, Sheng ZM, Guo ZY, Liu BC, Lu YR, Fang JX, Chen JE. Generating high-current monoenergetic proton beams by a circularly polarized laser pulse in the phase-stable acceleration regime. Phys Rev Lett 2008; 100:135003. [PMID: 18517963 DOI: 10.1103/physrevlett.100.135003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2007] [Indexed: 05/26/2023]
Abstract
A new ion acceleration method, namely, phase-stable acceleration, using circularly-polarized laser pulses is proposed. When the initial target density n(0) and thickness D satisfy a(L) approximately (n(0)/n(c))D/lambda(L) and D>l(s) with a(L), lambda(L), l(s), and n(c) the normalized laser amplitude, the laser wavelength in vacuum, the plasma skin depth, and the critical density of the incident laser pulse, respectively, a quasiequilibrium for the electrons is established by the light pressure and the space charge electrostatic field at the interacting front of the laser pulse. The ions within the skin depth of the laser pulse are synchronously accelerated and bunched by the electrostatic field, and thereby a high-intensity monoenergetic proton beam can be generated. The proton dynamics is investigated analytically and the results are verified by one- and two-dimensional particle-in-cell simulations.
Collapse
Affiliation(s)
- X Q Yan
- State Key Laboratory of Nuclear Physics and Technology, Institute of Heavy Ion Physics, Peking University, Beijing 100871, China.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
BACKGROUND Motorcycle crash victims form a high proportion of those killed or injured in road traffic crashes. Injuries to the head, following motorcycle crashes, are a common cause of severe morbidity and mortality. It seems intuitive that helmets should protect against head injuries but it has been argued that motorcycle helmet use decreases rider vision and increases neck injuries. This review will collate the current available evidence on helmets and their impact on mortality, and head, face and neck injuries following motorcycle crashes. OBJECTIVES To assess the effects of wearing a motorcycle helmet in reducing mortality and head and neck injury following motorcycle crashes. SEARCH STRATEGY We searched the Cochrane Injuries Group Specialised Register, Cochrane Central Register of Controlled Trials (The Cochrane Library issue 2, 2007), MEDLINE (up to April 2007), EMBASE (up to April week 16, 2007), CINAHL (January 1982 to February 2003), TRANSPORT (up to issue 12, 2006) (TRANSPORT combines the following databases: Transportation Research Information Services (TRIS) International Transport Research Documentation (ITRD) formerly International Road Research Documentation (IRRD), ATRI (Australian Transport Index) (1976 to Feb 2003), Science Citation Index were searched for relevant articles. Websites of traffic and road safety research bodies including government agencies were also searched. Reference lists from topic reviews, identified studies and bibliographies were examined for relevant articles. SELECTION CRITERIA We considered studies that investigated a population of motorcycle riders who had crashed, examining helmet use as an intervention and with outcomes that included one or more of the following: death, head, neck or facial injury. We included any studies that compared an intervention and control group. Therefore the following study designs were included: randomised controlled trials, non-randomised controlled trials, cohort, case-control and cross-sectional studies. Ecological and case series studies were excluded. DATA COLLECTION AND ANALYSIS Two authors independently screened reference lists for eligible articles. Two authors independently assessed articles for inclusion criteria. Data were abstracted by two independent authors using a standard abstraction form. MAIN RESULTS Sixty-one observational studies were selected of varying quality. Despite methodological differences there was a remarkable consistency in results, particularly for death and head injury outcomes. Motorcycle helmets were found to reduce the risk of death and head injury in motorcyclists who crashed. From four higher quality studies helmets were estimated to reduce the risk of death by 42% (OR 0.58, 95% CI 0.50 to 0.68) and from six higher quality studies helmets were estimated to reduce the risk of head injury by 69% (OR 0.31, 95% CI 0.25 to 0.38). Insufficient evidence was found to estimate the effect of motorcycle helmets compared with no helmet on facial or neck injuries. However, studies of poorer quality suggest that helmets have no effect on the risk of neck injuries and are protective for facial injury. There was insufficient evidence to demonstrate whether differences in helmet type confer more or less advantage in injury reduction. AUTHORS' CONCLUSIONS Motorcycle helmets reduce the risk of death and head injury in motorcycle riders who crash. Further well-conducted research is required to determine the effects of helmets and different helmet types on mortality, head, neck and facial injuries. However, the findings suggest that global efforts to reduce road traffic injuries may be facilitated by increasing helmet use by motorcyclists.
Collapse
Affiliation(s)
- B C Liu
- Richard Doll Building, Cancer Research UK Epidemiology Unit, Roosevelt Drive, University of Oxford, Oxford, UK, OX3 7LF.
| | | | | | | | | | | |
Collapse
|
44
|
Abstract
Using a resonance isobar model and an effective Lagrangian approach, from recent BES results on J/psi-->ppeta and psi-->pK+Lamda, we deduce the ratio between effective coupling constants of N*(1535) to KLamda and peta to be R=gN*(153)KLamda/gN*(1535)peta=1.3+/-0.3. With the previous known value of gN*(1535)peta, the obtained new value of gN*(1535)KLamda is shown to reproduce recent pp-->pK+Lamdanear-threshold cross section data as well. Taking into account this large N*KLamda coupling in the coupled channel Breit-Wigner formula for the N*(1535), its Breit-Wigner mass is found to be around 1400 MeV, much smaller than the previous value of about 1535 MeV obtained without including its coupling to KLamda. The implication on the nature of N*(1535) is discussed.
Collapse
Affiliation(s)
- B C Liu
- Institute of High Energy Physics, P.O. Box 918(4), Beijing 100049, China
| | | |
Collapse
|
45
|
Lyu SC, Liu BC, Lee TJ, Liu ZY, Yang CW, Park CY, Lee CJ. Synthesis of high-quality single-walled carbon nanotubes by catalytic decomposition of C2H2. Chem Commun (Camb) 2003:734-5. [PMID: 12703797 DOI: 10.1039/b300109a] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
High-quality single-walled carbon nanotubes free of defects and amorphous carbon coating have been produced by catalytic decomposition of C2H2 over Fe-Mo/Al2O3 catalyst.
Collapse
Affiliation(s)
- S C Lyu
- Department of Nanotechnology, Hanyang University, Seoul 133-791, Korea
| | | | | | | | | | | | | |
Collapse
|
46
|
Liu BC, LaRose I, Weinstein LJ, Ahn M, Weinstein MH, Richie JP. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer 2001; 92:1943-8. [PMID: 11745269 DOI: 10.1002/1097-0142(20011001)92:7<1943::aid-cncr1713>3.0.co;2-m] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Vertebrates have special structures at the ends of their chromosomes, known as telomeres, which may provide the chromosomes with stability and protect them from exonucleolytic degradation. The shortening of telomeric DNA with each cell division may lead to cell cycle arrest and/or apoptosis of a normal human somatic cell. Telomerase, an RNA-dependent DNA polymerase, elongates the 3'-ends of telomeric DNA. Thus, the presence of telomerase activity may reflect a cell's potential immortal state. The telomerase complex is comprised of several subunits. In the current study, the authors describe the use of laser capture microdissection (LCM) to procure pure matched tumor and normal cell populations from histologic sections and to determine the expression of telomerase subunits in these purified samples. METHODS Pure matched tumor and normal prostate epithelial cells were procured by LCM using fresh frozen tissue samples obtained from patients undergoing radical prostatectomy. RNA was extracted from LCM captured cells, and the subunits for telomerase were assayed by reverse transcriptase-polymerase chain reaction. RESULTS In 18 samples that were captured with LCM, only the catalytic subunit of telomerase, or hTERT, was found to be discriminatory between tumor cells (17 of 18 specimens, 94.4%) and nontumor cells (none of 18 specimens). TP1, a protein that has been shown to be associated with telomerase activity, was expressed in 3 of 18 normal cells (16.7%) and 15 of 18 tumor cells (83.3%). The RNA subunit of telomerase, or hTR, was expressed in 10 of 18 normal cells (55.6%) and 18 of 18 tumor cells (100%). There was no apparent correlation between telomerase subunit(s) expression and Gleason sum score. CONCLUSIONS Molecular analyses of LCM cells from prostate carcinoma patient samples demonstrated transcriptional up-regulation of all telomerase subunits in the prostatic epithelium. However, only the catalytic subunit of telomerase, hTERT, was found to be discriminatory between neoplastic versus normal cells (94.4% vs. 0%). This finding suggests that the hTERT subunit may be a useful marker for the detection of prostate carcinoma and/or a potential target for therapy.
Collapse
Affiliation(s)
- B C Liu
- Molecular Urology Laboratory, Department of Surgery/Urology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA.
| | | | | | | | | | | |
Collapse
|
47
|
Liu BC, Ma KL, Ye YY, Liu NF, Ruan XZ. Effects of L-arginine on the proliferation of human renal mesangial cells and production of extracellular matrix. Acta Pharmacol Sin 2001; 22:756-60. [PMID: 11749852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
AIM To investigate the effect of L-arginine (L-arg) on the proliferation of human mesangial cells and production of collagen. METHODS The influence of L-arg on the cell proliferation was determined by MTT assay, immunocytochemical detection of expression of proliferative cell nuclear antigen (PCNA), and flow cytometrical analysis of cell cycle. Procollagen III and total collagen level in the supernatant and expression of collagen IV mRNA in human mesangial cells were determined by radioimmunoassay, hydroxyproline colorimetric assay, and reverse transcription polymerase chain reaction (RT-PCR). RESULTS L-Arg induced inhibition of human mesangial cell lines (HMCL) in a concentration- and time-dependent manner. Immunocytochemical study for PCNA showed the number of cells was decreased, though the percentage of PCNA positive cells was increased in L-arg-treated group. Flow cytometrical analysis showed that cells in S and G2/-M phases were markedly increased in L-arg-treated group compared with those in control group. Furthermore, L-arg significantly inhibited the production of procollagen III and total collagen in the supernatants determined by radioimmunoassay and hydroxyproline colorimetric assay (P < 0.05 and 0.01, respectively) and inhibited the expression of collagen IV mRNA determined by RT-PCR (P < 0.01). CONCLUSION L-arg could exert an inhibitory effect on the proliferation of human mesangial cells and production of extracellular components, which strongly suggested its potential therapeutic role in the chronic renal scarring.
Collapse
Affiliation(s)
- B C Liu
- Renal Division, Zhong Da Hospital, Southeast University, Nanjing 210009, China
| | | | | | | | | |
Collapse
|
48
|
Liu NF, Sun ZL, Liu BC. Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis. Acta Pharmacol Sin 2000; 21:276-80. [PMID: 11324431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
AIM To study the effect of removal of hemodialysis using acetate membrane on serum advanced glycosylation end products (AGEP) in 36 patients (59.1 +/- 1.6) with end stage renal disease (ESRD). METHODS Serum AGEP levels were determined with quantitative fluorescence spectrometry, flow injection analysis (FIA), and competitive enzyme-linked immunosorbent assay (ELISA) using a polyclonal antibody directed against AGEP. RESULTS The serum AGEP levels in patients with ESRD quantified by fluorescence spectrometry, FIA, and ELISA were higher than those in controls [(25 +/- 5) vs (7.5 +/- 1.5), (6.1 +/- 1.8) vs (1.4 +/- 0.5), and (37 +/- 20) vs (9 +/- 10) kU/L, respectively] and markedly reduced to [(22 +/- 6), (4.2 +/- 1.4), and (19 +/- 14) kU/L, respectively] after hemodialysis. CONCLUSION Increased serum AGEP levels in the circulation of patients with ESRD were reduced effectively by hemodialysis.
Collapse
Affiliation(s)
- N F Liu
- Department of Cardiology, First Affiliated Hospital, Nanjing Railway Medical College, Nanjing 210009, China.
| | | | | |
Collapse
|
49
|
Abstract
Biomarkers for human bladder cancer are currently available and more are being developed. However, the ultimate goal of diagnosing bladder cancer consistently in a noninvasive fashion has not yet been achieved. Telomerase is an enzyme that may play a role in maintaining telomere sequences in the ends of chromosomes and its activity may reflect the presence of immortal or cancer cells. In this article, we reviewed the potential applications of telomerase in the diagnosis, monitoring, and treatment of human bladder cancer.
Collapse
Affiliation(s)
- B C Liu
- Division of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| | | |
Collapse
|
50
|
Abstract
The effect of progesterone on the serotonin type 3 (5-HT3) receptor-mediated response was studied in acutely dissociated rat nodose ganglion neurons by using the whole-cell voltage-clamp technique. Progesterone rapidly and reversibly inhibited 5-HT-induced currents in a dose-dependent manner, with an EC50 of 31 microM and a maximal inhibition of 75%. Neither the 5-HT response nor inhibition of the 5-HT response by extracellularly applied progesterone was significantly affected by inclusion of a saturating concentration of progesterone in the electrode buffer, arguing that progesterone acted at the extracellular surface of the membrane. Progesterone also inhibited the 5-HT response non-competitively by a voltage- and agonist-independent mechanism that was distinct from that of open-channel blockers.
Collapse
Affiliation(s)
- F S Wu
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
| | | | | |
Collapse
|